

<p><b>(51) International Patent Classification :</b></p> <p style="text-align: center;"><b>Not classified</b></p>	A2	<p><b>(11) International Publication Number:</b> WO 00/</p> <p><b>(43) International Publication Date:</b> 20 July 2000 (20.07.00)</p>																																																																																																
<p><b>(21) International Application Number:</b> PCT/US00/00942</p> <p><b>(22) International Filing Date:</b> 14 January 2000 (14.01.00)</p> <p><b>(30) Priority Data:</b></p> <table style="width: 100%;"> <tr> <td style="width: 40%;">60/116,380</td> <td style="width: 30%;">14 January 1999 (14.01.99)</td> <td style="width: 30%;">US</td> </tr> <tr> <td>60/132,017</td> <td>30 April 1999 (30.04.99)</td> <td>US</td> </tr> <tr> <td>60/175,365</td> <td>10 January 2000 (10.01.00)</td> <td>US</td> </tr> </table> <p><b>(71) Applicant (for all designated States except US):</b> AMYLIN PHARMACEUTICALS, INC. [US/US]; 9373 Towne Centre Drive, Suite 250, San Diego, CA 92121 (US).</p> <p><b>(72) Inventors; and</b></p> <p><b>(75) Inventors/Applicants (for US only):</b> YOUNG, Andrew [US/US]; P. O. Box 60591, Point Loma, CA 92166 (US). GEDULIN, Bronislava [US/US]; 12825 Stebick Court, San Diego, CA 92131 (US).</p> <p><b>(74) Agent:</b> DUFT, Bradford, J.; Lyon &amp; Lyon LLP, 633 West Fifth Street, Suite 4700, Los Angeles, CA 90071-2066 (US).</p>	60/116,380	14 January 1999 (14.01.99)	US	60/132,017	30 April 1999 (30.04.99)	US	60/175,365	10 January 2000 (10.01.00)	US	<p><b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b></p> <p><i>Without international search report and to be republished upon receipt of that report.</i></p>																																																																																								
60/116,380	14 January 1999 (14.01.99)	US																																																																																																
60/132,017	30 April 1999 (30.04.99)	US																																																																																																
60/175,365	10 January 2000 (10.01.00)	US																																																																																																
<p><b>(54) Title:</b> METHODS FOR GLUCAGON SUPPRESSION</p>																																																																																																		
<table style="margin-left: auto; margin-right: auto;"> <tr> <td>His</td><td>Ser</td><td>Asp</td><td>Gly</td><td>Thr</td><td>Phe</td><td>Thr</td><td>Ser</td><td>Asp</td><td>Leu</td><td>Ser</td><td>Lys</td><td>Gln</td><td>Met</td><td>Glu</td><td>Glu</td> </tr> <tr> <td>1</td><td></td><td></td><td></td><td>5</td><td></td><td></td><td></td><td></td><td>10</td><td></td><td></td><td></td><td></td><td>15</td><td></td> </tr> <tr> <td>Glu</td><td>Ala</td><td>Val</td><td>Arg</td><td>Leu</td><td>Phe</td><td>Ile</td><td>Glu</td><td>Trp</td><td>Leu</td><td>Lys</td><td>Asn</td><td>Gly</td><td>Gly</td><td>Pro</td><td>Ser</td> </tr> <tr> <td></td><td></td><td></td><td>20</td><td></td><td></td><td></td><td></td><td>25</td><td></td><td></td><td></td><td></td><td>30</td><td></td><td></td> </tr> <tr> <td>Ser</td><td>Gly</td><td>Ala</td><td>Pro</td><td>Pro</td><td>Pro</td><td>Ser-NH<sub>2</sub></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td> </tr> <tr> <td></td><td></td><td></td><td>35</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td> </tr> </table>			His	Ser	Asp	Gly	Thr	Phe	Thr	Ser	Asp	Leu	Ser	Lys	Gln	Met	Glu	Glu	1				5					10					15		Glu	Ala	Val	Arg	Leu	Phe	Ile	Glu	Trp	Leu	Lys	Asn	Gly	Gly	Pro	Ser				20					25					30			Ser	Gly	Ala	Pro	Pro	Pro	Ser-NH <sub>2</sub>													35												
His	Ser	Asp	Gly	Thr	Phe	Thr	Ser	Asp	Leu	Ser	Lys	Gln	Met	Glu	Glu																																																																																			
1				5					10					15																																																																																				
Glu	Ala	Val	Arg	Leu	Phe	Ile	Glu	Trp	Leu	Lys	Asn	Gly	Gly	Pro	Ser																																																																																			
			20					25					30																																																																																					
Ser	Gly	Ala	Pro	Pro	Pro	Ser-NH <sub>2</sub>																																																																																												
			35																																																																																															
<p><b>(57) Abstract</b></p> <p>Methods for use of an exendin, an exendin agonist, or a modified exendin or exendin agonist having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, for lowering glucagon levels and/or suppressing glucagon secretion in a subject are provided. These methods are useful in treating hyperglucagonemia and other conditions that would be benefited by lowering plasma glucagon or suppressing glucagon secretion.</p>																																																																																																		